Previous 10 | Next 10 |
Q3 Revenue of $ 8.2 million up 2 % versus Prior Year Q3 Adjusted EBITDA Positive Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- ...
Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved ...
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved...
Interpace Biosciences ( OTCQX:IDXG ) on Wednesday said it had closed the sale of its pharma services business to Flagship Biosciences. IDXG CEO Thomas Burnell said with the completion of the deal, the company's operating cash flow is expected to improve by nearly $5M annually....
Interpace Transitions to focused Molecular Diagnostics Business Disposition of Pharma Services Expected to I mprove Operating Cash Flow by nearly $ 5 million A nnually PARSI...
Interpace Biosciences press release (OTCQX:IDXG): Q1 GAAP EPS of -$0.53. Revenue of $10.38M (+5.6% Y/Y). March 31, 2022 cash balance was $2.9 million, net of restricted cash and May 12, 2022 cash balance was $3.3 million, net of restricted cash. For further details see: Interpace Biosci...
PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quar...
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tools f...
Interpace Biosciences press release (OTCQX:IDXG): Q4 GAAP EPS of -$0.89. Revenue of $10.86M (+12.5% Y/Y). For further details see: Interpace Biosciences GAAP EPS of -$0.89, revenue of $10.86M
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...